Table 1.
Clinical trials recently started to investigate the safety and efficacy of oncolytic viruses in cancer patients*
| Agent |
Indication |
Phase |
Status |
Route |
Notes |
Ref. |
|---|---|---|---|---|---|---|
| Ad5-yCD/mutTKSR39rep-hIL12 | Prostate carcinoma | I | Recruiting | Intraprostatic | As single agent | NCT02555397 |
| Cavatak™ | Bladder carcinoma | I | Recruiting | Intravesical | Optionally combined with low-dose mitomycin C | NCT02316171 |
| Melanoma | I | Recruiting | Intratumoral | Combined with ipilimumab | NCT02307149 | |
| Combined with pembrolizumab | NCT02565992 | |||||
| CG0070 | Bladder carcinoma | II | No longer available | Intravesical | As single agent | NCT02143804 |
| Recruiting | Intravesical | As single agent | NCT02365818 | |||
| DNX-2401 | Brain tumors | I | Recruiting | Intratumoral | Combined with IFNγ | NCT02197169 |
| G207 | Brain tumors | I | Not yet recruiting | Intratumoral | Optionally combined with radiation therapy | NCT02457845 |
| HF10 | Melanoma | II | Recruiting | Intratumoral | Combined with ipilimumab | NCT02272855 |
| Solid tumors | I | Recruiting | Intratumoral | As single agent | NCT02428036 | |
| Imlygic® | Hepatocellular carcinoma | I | Not yet recruiting | Intratumoral | As single agent | NCT02509507 |
| Melanoma | n.a. | Enrolling by invitation | Intratumoral | As single agent | NCT02173171 | |
| II | Recruiting | Intratumoral | As single agent | NCT02366195 | ||
| Combined with surgery | NCT02211131 | |||||
| III | Active, not recruiting | Intratumoral | Combined with pembrolizumab | NCT02263508 | ||
| Available | Intratumoral | As single agent | NCT02147951 | |||
| NCT02297529 | ||||||
| Soft tissue sarcoma | I/II | Recruiting | Intratumoral | Combined with radiotherapy | NCT02453191 | |
| JX-594 | Hepatocellular carcinoma | III | Not yet recruiting | Intratumoral | Combined with sorafenib | NCT02562755 |
| MG1-MA3 | Solid tumors | I/II | Recruiting | Intravenous | Combined with a MAGEA3-encoding adenovirus | NCT02285816 |
| MV-NIS | Gynecological tumors | II | Recruiting | Intraperitoneal | As single agent | NCT02364713 |
| Multiple myeloma | II | Recruiting | Intravenous | Combined with cyclophosphamide | NCT02192775 | |
| OBP-301 | Solid tumors | I | Not yet recruiting | Intratumoral | As single agent | NCT02293850 |
| Reolysin® | Brain tumors | I | Recruiting | Intravenous | Combined with GM-CSF s.c. | NCT02444546 |
| Multiple myeloma | I | Recruiting | Intravenous | Combined with dexamethasone plus a proteasomal inhibitor | NCT02101944 | |
| NCT02514382 | ||||||
| Toca 511 | Brain tumors | II/III | Not yet recruiting | Intratumoral | Combined with 5-FC and standard chemotherapy | NCT02414165 |
| Solid tumors | I/II | Recruiting | Intratumoral Intravenous | Combined with 5-FC | NCT02576665 |
Abbreviations: 5-FC, 5-fluorocytosine; GM-CSF, granulocyte macrophage colony-stimulating factor; IFNγ, interferon γ; MAGEA3, melanoma antigen family A3; s.c.,sub cutem.
*initiated between 2014, March 1st and 2015, October 31th.